Comparative Pharmacology
Head-to-head clinical analysis: ELINEST versus PIRMELLA 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELINEST versus PIRMELLA 1 35.
ELINEST vs PIRMELLA 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethinyl estradiol is an estrogen; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity. The combination suppresses gonadotropins, inhibiting ovulation.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Additionally, causes cervical mucus thickening and endometrial atrophy, reducing sperm penetration and implantation.
0.5 mg orally once daily.
One tablet orally once daily for 21 days, followed by 7 placebo tablets during the withdrawal bleed.
None Documented
None Documented
Terminal elimination half-life of estradiol (E2) is ~13-16 h, but due to the prodrug nature and accumulation of estrogen metabolites, the effective half-life during continuous use is ~36 h, supporting once-daily dosing.
Terminal half-life 24–30 hours for ethinyl estradiol; 13–18 hours for norethindrone. Steady state reached after 7–10 days.
~68% renal (50% unchanged, ~18% as inactive metabolites), ~30% biliary/fecal, with enterohepatic recycling of drug and estrogen conjugates.
Renal 60–80% as metabolites (glucuronide conjugates), biliary/fecal 10–20%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive